evipedia.ai
← Back

Microdosing LSD for Health & Longevity

Evidence Review created on 08/04/2026 using AI4L / Opus 5

Also known as: LSD Microdosing, Low-Dose LSD, Sub-Perceptual LSD Dosing, Lysergic Acid Diethylamide Microdosing, LSD-25 Microdosing

Motivation

LSD (lysergic acid diethylamide) is a synthetic compound derived from a fungus that grows on rye grain. At full strength it produces profound changes in perception and thought. Microdosing means taking a small fraction of that amount, too little to alter perception noticeably, on a repeating schedule of every second or third day. The interest lies in that gap: whether so small an amount can still shift mood and brain health.

The practice has roots in the earliest era of research into these compounds and was revived in the 2010s through self-experimentation networks and a widely circulated guidebook. Survey work now estimates that millions of adults have tried very low doses of a psychedelic substance. People who do so most often describe steadier mood, sharper focus and better sleep, and many frame the practice as an investment in long-term brain health rather than as recreation.

This review examines microdosing LSD through a health and longevity lens: which reported effects survive comparison against an inactive tablet nobody can tell apart, how well it is tolerated and what is known about long-term safety, how the practice is typically structured, and which questions the current evidence leaves open.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overviews of low-dose psychedelic use from expert commentators, selected to give context that the primary trial reports do not provide.

  • Dr. Matthew Johnson: Psychedelic Medicine - Andrew Huberman

    A long-form interview with a Johns Hopkins psychedelic researcher covering the pharmacology of LSD and related compounds, what controlled trials do and do not show, flashbacks, and the populations at heightened risk. It is the most accessible expert framing of why full-dose findings cannot simply be scaled down to microdoses.

  • Microdosing psychedelics may assist people in making health-related behavior changes - Rhonda Patrick

    A research digest of survey data from 365 adults with microdosing experience, reporting that sleep, contemplative practice and physical activity were the habits most often changed. It is useful precisely because it separates a possible indirect route to health benefit — habit change — from any direct pharmacological effect.

  • #182 – David Nutt: Psychedelics & Recreational Drugs - Peter Attia

    A conversation with the neuropsychopharmacologist who chaired the United Kingdom’s drug advisory council, covering how LSD came to be scheduled, the mismatch between legal classification and measured harm, and the research obstacles this creates. It supplies the regulatory and historical context that shapes why the evidence base is as thin as it is.

  • RHR: The Emerging Field of Psychedelic-Assisted Psychotherapy, with Dr. Ingmar Gorman - Chris Kresser

    A podcast conversation with the co-founder of a psychedelic-therapy training organisation, covering the state of the clinical research, how these compounds are actually administered in a therapeutic setting, and where the practice is heading. It marks out the boundary between supervised full-dose therapy and the unsupervised sub-perceptual practice this review examines.

  • Anxiety and Anxiety Disorders: Overview - Weeks et al.

    A protocol overview whose psychedelic therapy subsection traces the two historical research trajectories for these compounds — repeated low doses used to enhance psychotherapy, and single transformative high doses — and summarises the trial evidence for LSD in anxiety. It is the clearest statement of the low-dose therapeutic lineage from which modern microdosing descends.

Relevant content was located on all five priority-expert platforms, so all five list positions are occupied by priority-expert sources and the list has not been padded with marginal material. The academic narrative review of the cardiac-fibrosis question that would otherwise sit here is cited in the Potential Risks and Emerging Research sections instead.

Grokipedia

  • Microdosing

    The entry covers the definition of sub-hallucinogenic dosing, the common schedules, the controlled-trial record and the placebo debate in a single continuous article. It is a useful orientation to how the practice is described and contested outside the clinical literature.

Examine

  • LSD

    A short evidence-oriented profile of the compound, its discovery and its preliminary therapeutic signals in depression and anxiety, with a linked research feed that includes a summary specifically on LSD microdosing in healthy adults. It is the most conservative independent read on where the human evidence currently sits.

ConsumerLab

No ConsumerLab article on LSD or on microdosing exists. ConsumerLab tests dietary supplements, foods and consumer health products; it does not cover controlled substances or prescription medications, and LSD is a controlled substance with no legal consumer product to test.

Systematic Reviews

The following systematic reviews (structured surveys of all studies meeting pre-set criteria) and meta-analyses (statistical poolings of results across studies) cover the controlled and observational literature on psychedelic microdosing, with LSD as the dominant compound studied.

Mechanism of Action

LSD is a semisynthetic ergoline, chemically derived from ergot alkaloids produced by the fungus Claviceps purpurea. Its actions relevant to microdosing are best understood at three levels: receptor binding, downstream circuit effects, and pharmacokinetics.

  • Serotonin 2A receptor agonism: LSD is a partial agonist at the serotonin 2A receptor (5-HT2A — the serotonin receptor subtype that mediates the perception-altering effects of classic psychedelics and is densely expressed on cortical pyramidal neurons). At full doses, occupancy of this receptor drives the altered state; at 5–20 micrograms, occupancy is low enough that overt perceptual change is usually absent while measurable electrophysiological and subjective effects persist. The crystal structure of LSD bound to a human serotonin receptor showed that an extracellular loop folds over the binding pocket, giving unusually slow dissociation and explaining why effects outlast plasma levels.

  • Broader receptor promiscuity: LSD also binds serotonin 1A, 2B, 2C, 6 and 7 receptors and dopamine D1 and D2 receptors. The serotonin 2B interaction (5-HT2B — a serotonin receptor present on heart valve tissue) is pharmacologically minor for the subjective effect but is the basis of the long-term cardiac safety question, since sustained 5-HT2B agonism drives fibroblast proliferation on heart valves. Tagen et al., 2023 established that LSD binds 5-HT2B with potency equal to or greater than 5-HT2A and acts there as a partial agonist; its authors are affiliated with Delos Therapeutics, a company developing psychedelic-derived compounds, and therefore hold a direct commercial interest in how this risk is characterised.

  • Cortical plasticity and network effects: Classic psychedelics are described as psychoplastogens — compounds that promote structural and functional adaptation in cortical neurons. In humans at microdose levels, Murphy et al., 2024 detected modulation of long-term potentiation (LTP — the strengthening of synaptic connections that underlies learning) using thalamo-cortical modelling of electroencephalography (EEG — a recording of the brain’s electrical activity from the scalp) data. This paper belongs to the Auckland trial programme (the MDLSD healthy-volunteer trial and the LSDDEP depression trials, reported across Murphy, Allen, Morse and Daldegan-Bueno and colleagues) that supplies most of the controlled evidence cited throughout this review; it was supported in part by MindBio Therapeutics Ltd, a company developing microdosed LSD as a commercial product, alongside the Health Research Council of New Zealand. That sponsor has a direct financial interest in a positive result, and the same interest applies to every Auckland trial cited below. Murray et al., 2022 found reduced broadband oscillatory power and altered event-related potentials at 13 and 26 micrograms, and Bershad et al., 2020 reported altered resting-state connectivity between the amygdala (the brain’s threat-detection hub) and cortex at 13 micrograms.

  • Competing mechanistic accounts: Two explanations compete for the reported benefits. The pharmacological account holds that partial 5-HT2A engagement produces a genuine, dose-dependent shift in affect and cortical excitability. The expectancy account holds that the observable effects are largely the product of belief and unblinding, and is supported by Szigeti et al., 2021, whose 191-participant self-blinding study found that microdose and placebo groups both improved with no between-group difference once blind-breaking was accounted for. Polito & Liknaitzky, 2024 argue the reverse: that dose-dependent neurobiological and physiological changes have been demonstrated, that measured expectancy effects are small, and that a placebo verdict is therefore premature. Both accounts remain live; neither has been decisively excluded.

  • Anti-inflammatory hypothesis: Preclinical work indicates that 5-HT2A signalling exerts potent anti-inflammatory effects at very low concentrations, which is the stated rationale for Family et al., 2020, a trial in older adults framed explicitly around neuroinflammation in neurodegenerative disease that was sponsored by Eleusis Benefit Corporation, a company developing LSD as a pharmaceutical and therefore holding a direct commercial interest in the hypothesis it tested. No human study has yet measured inflammatory markers as a primary endpoint under a microdosing regimen.

  • Key pharmacological properties: Oral LSD base reaches peak plasma concentration at roughly 1.1 hours, with an elimination half-life of about 2.7 hours (range 1.5–6.2) and dose-proportional exposure across 5, 10 and 20 micrograms, giving peak concentrations of 151, 279 and 500 picograms per millilitre respectively (Holze et al., 2021). Sublingual administration behaves similarly: Morse et al., 2025 modelled a one-compartment fit with clearance of 7.78 litres per hour per 70 kilograms, central volume of distribution 32.9 litres per 70 kilograms, peak at 1.51 hours and half-life 3.08 hours. LSD is not highly tissue-selective; it distributes widely and crosses the blood-brain barrier readily. Metabolism takes place in the liver by oxidation, producing the inactive metabolite 2-oxo-3-hydroxy-LSD, with the metabolites excreted by the kidneys. Morse et al. found that CYP2D6, CYP1A2, CYP2B6 and CYP2C9 genotypes (cytochrome P450 enzymes — the liver’s main drug-processing enzyme family, of which CYP2D6 handles many psychiatric medications) each appeared qualitatively to influence plasma concentration.

Historical Context & Evolution

  • Original intended use: LSD was first synthesised in 1938 by Albert Hofmann at Sandoz Laboratories during a programme investigating ergot derivatives as circulatory and obstetric stimulants. Its psychoactivity was discovered accidentally in 1943. Sandoz marketed it from 1947 as Delysid, positioned for two purposes: as an adjunct in analytic psychotherapy, and as a means for psychiatrists to experience an induced psychosis-like state.

  • The early low-dose record: Doses in this early era were not uniformly large. Polito & Liknaitzky, 2022 recovered a set of infrequently cited pre-prohibition studies using low doses and documented what they actually reported: changes in pain perception, time perception, conscious state and neurophysiology. These findings were not overturned by later work; they were simply orphaned when research stopped. The analgesic line in particular was substantiated in terminally ill patients before LSD was scheduled worldwide, a history revisited directly by Ramaekers et al., 2021 rather than through secondary characterisation.

  • Prohibition and its evidentiary consequences: LSD was placed under the 1971 United Nations Convention on Psychotropic Substances and became Schedule I in the United States. Research was not refuted; it was administratively halted. This matters for how the older literature should be read: the absence of follow-up is a policy artefact, not a scientific verdict, and claims that early psychedelic research was discredited conflate the political collapse of the field with an evidentiary one.

  • Revival as microdosing: The specific practice of repeated sub-perceptual dosing was codified in the 2010s. Fadiman & Korb, 2019 published the first structured exploration, drawing on self-reports collected through an open protocol of one dosing day followed by two non-dosing days. This primary source, rather than later summaries of it, is where the now-standard schedule originates. Its methodological limitations are real — self-selected, self-sourced, unblinded — but its findings framed the questions that controlled trials were later built to test.

  • How scientific opinion has shifted, and why: Between 2019 and 2022 the prevailing reading moved toward expectancy, driven by the large self-blinding study of Szigeti et al., 2021. Since 2023 the picture has become less settled again rather than more: Murphy et al., 2023 found dose-day mood effects that persisted after controlling for pre-intervention expectancy, and Allen et al., 2024 found an objective sleep change difficult to attribute to belief. Simultaneously, Pinhas et al., 2026 closed off the cognitive-enhancement claim entirely. The current position is therefore not a consensus that microdosing works or does not work, but a narrower set of findings: real acute effects, no demonstrated durable ones, and one demonstrated decrement.

Expected Benefits

High 🟩 🟩 🟩

No benefit of microdosing LSD currently meets this evidence standard. No benefit has been demonstrated by consistent, adequately powered, blinded randomised controlled trials (RCTs — studies in which participants are randomly assigned to receive the active compound or an inactive dummy) or by a positive meta-analysis.

Medium 🟩 🟩

Acute Mood Elevation and Subjective Wellbeing on Dosing Days ⚠️ Conflicted

Repeated microdoses produce measurable same-day lifts in mood-adjacent states, but the randomised evidence points in opposite directions. In the largest home-administered trial, 80 healthy men received 10 micrograms or placebo every third day for six weeks; daily questionnaires showed credible improvement in creativity, connectedness, energy, happiness, irritability and wellness on dose days relative to non-dose days, and these effects persisted when pre-intervention expectancy was statistically controlled (Murphy et al., 2023). A dose-finding study in 24 healthy volunteers found increased positive mood, friendliness and arousal (Hutten et al., 2020). Against these, de Wit et al., 2022 found negligible mood change with four repeated doses of 13 or 26 micrograms in 56 participants, and the 191-participant self-blinding study of Szigeti et al., 2021 found microdose and placebo groups improving alike; the discrepancy plausibly reflects dosing schedule, sample size and how tightly dose-day and non-dose-day ratings were separated. The grade is held at Medium rather than High for that reason and because even the positive trials found no change from baseline to endpoint on any validated instrument.

Magnitude: Credible improvement (greater than 99% posterior probability — the statistical likelihood, given the data, that the effect is real) on six daily wellbeing scales on dosing days, with no measurable change in overall mood between baseline and six weeks.

Increased Sleep Duration the Night After Dosing

Microdosing lengthened objectively recorded sleep on the night following each dose. In a Phase 1 randomised controlled trial, 80 healthy adult men self-administered 10 micrograms of LSD or placebo every third day for six weeks while wearing a commercial sleep tracker, generating 3,231 nights of data (Allen et al., 2024). Sleep was not shortened on the dosing day itself, and the proportion of time in each sleep stage and daily physical activity were unchanged. Because the measure is objective and device-recorded rather than self-reported, the authors argued it is difficult to explain as a placebo response. It has not yet been replicated in an independent cohort or in women, which caps the grade at Medium.

Magnitude: 24.3 additional minutes of sleep per night the night after dosing (95% confidence interval 10.3–38.3 minutes; the confidence interval is the range within which the true effect most likely lies).

Low 🟩

Reduction of Depressive Symptoms

An eight-week open-label Phase 2A trial gave 19 adults with major depressive disorder 16 sublingual doses of LSD, starting at 8 micrograms and titrating between 6 and 20 micrograms twice weekly, with 15 participants continuing existing antidepressant medication (Daldegan-Bueno et al., 2026). Depression scores fell substantially and the reduction was sustained for up to six months. The companion mood and pharmacokinetic analysis found improvement in mood-related states on dosing days but no change in daily depression severity, suggesting the headline improvement may reflect trial participation and expectancy as much as pharmacology (Daldegan-Bueno et al., 2026). The absence of a control arm and the small, predominantly male sample keep this at Low pending the randomised successor trial.

Magnitude: 59.5% reduction in clinician-rated depression score at end of intervention in an uncontrolled sample of 19.

Low doses increased the brain’s electrophysiological response to reward, a signal relevant to anhedonia (the reduced capacity to feel pleasure that characterises much of depression). In a placebo-controlled study in 18 healthy adults, 13 micrograms increased the reward positivity and late-positive potential components of the event-related potential to rewarding feedback, and both 13 and 26 micrograms increased the feedback-P3 component to positive feedback (Glazer et al., 2023). The finding is mechanistically coherent with the mood observations above and with altered amygdala connectivity at similar doses. It rests on single-laboratory neurophysiological endpoints in healthy volunteers rather than on clinical outcomes, and no trial has linked the signal to symptom change.

Magnitude: Increased reward positivity and late-positive potential at 13 micrograms, and increased feedback-P3 at both 13 and 26 micrograms, versus placebo in 18 participants.

Analgesia ⚠️ Conflicted

Evidence for pain relief is directly contradictory. A within-subject placebo-controlled study in 24 healthy volunteers found that 20 micrograms significantly increased cold-pressor tolerance and reduced rated painfulness and unpleasantness, an effect still present 5 hours after dosing (Ramaekers et al., 2021). A later randomised placebo-controlled study using four administrations of 15 micrograms found no analgesic effect on any measure across the whole sample, with a marginal effect appearing only in a post-hoc subgroup that had not hit a ceiling at baseline (Cavarra et al., 2025). The discrepancy is plausibly explained by dose (20 versus 15 micrograms), by the ceiling effect in the later study’s task, and by single versus repeated administration. Historical work in terminally ill patients used full doses and does not bear on the microdose range.

Magnitude: Increased cold-pressor tolerance and reduced pain ratings at 20 micrograms in one trial; no effect on any pain measure at 15 micrograms in a second.

Markers of Cortical Plasticity

Microdoses produce changes in electrophysiological indices of synaptic plasticity. Thalamo-cortical modelling of EEG data from a randomised controlled trial detected modulation of long-term potentiation following 10 microgram doses (Murphy et al., 2024), and 13 and 26 microgram doses reduced broadband oscillatory power and altered event-related potentials (Murray et al., 2022). These are the most plausible bridge between acute dosing and any durable benefit, and are the reason interest persists despite negative behavioural endpoints. However, no study has connected these markers to a clinical or cognitive outcome, and one trial found no change in circulating brain-derived neurotrophic factor (BDNF — a protein that supports the growth and survival of neurons) with microdosing (Morse et al., 2025).

Magnitude: Not quantified in available studies.

Speculative 🟨

Anti-Inflammatory and Neuroprotective Effects Relevant to Brain Aging

The proposition that repeated sub-perceptual dosing could slow neuroinflammatory contributions to cognitive decline rests on preclinical receptor pharmacology, not on human outcome data. Activation of 5-HT2A at very low concentrations has anti-inflammatory effects in animal and cell models, and this rationale motivated a Phase 1 trial in 48 healthy volunteers with a mean age of 62.9 years, who received 5, 10 or 20 micrograms every fourth day over 21 days; the trial established tolerability and was framed as supporting development for Alzheimer’s disease, but measured no inflammatory or cognitive benefit (Family et al., 2020). That study was sponsored by Eleusis Benefit Corporation, a company developing LSD as a pharmaceutical, which is a direct commercial interest in the hypothesis. No trial has since tested inflammatory or neurodegenerative endpoints under a microdosing regimen, so the basis remains mechanistic only.

Indirect Health Gains Through Behavioural Change

Some of the reported benefit may operate through habit rather than pharmacology. Survey data from 365 adults with microdosing experience found that most attributed at least one health behaviour change to the practice, with sleep the most common, followed by contemplative practice and physical activity, and with reduced alcohol consumption far more common than increased. Change was predicted by having started with an explicit intention to improve habits, and not by dose, schedule or mental-health diagnosis — a pattern more consistent with a motivational or expectancy pathway than a direct drug effect. The basis is retrospective, self-selected self-report with no control condition, so no controlled evidence supports this route.

Benefit-Modifying Factors

  • Cytochrome P450 genotype: Morse et al., 2025 found that CYP2D6, CYP1A2, CYP2B6 and CYP2C9 genotypes each qualitatively influenced plasma LSD concentration after a fixed 10 microgram sublingual dose. Slower metabolisers reach higher exposure from the same nominal dose, which shifts them further along the dose-response curve toward perceptible effects; faster metabolisers may fall below the threshold dose entirely. The authors proposed these genotypes as candidate biomarkers of response.

  • Baseline mood and depression severity: Effect sizes are consistently larger in samples selected for depressive symptoms than in healthy volunteers. Healthy-volunteer trials found negligible change in overall mood, whereas the open-label depression trial reported substantial symptom reduction. This is the classic floor-effect pattern: there is little room for a mood-elevating compound to demonstrate benefit in people whose mood is already normal.

  • Baseline sleep quality: The sleep-extension finding was obtained in healthy men without sleep complaints. Whether the effect is larger, smaller or absent in people with insomnia or restricted sleep opportunity has not been tested, and the direction is not predictable from the mechanism.

  • Expectancy and prior belief: Expectancy is a genuine modifier rather than only a confound. Szigeti & Heifets, 2024 show that in psychedelic trials, participants’ guesses about their allocation predict outcome, and that unblinding is near-universal at doses producing any perceptible effect. Anyone entering the practice with strong positive expectation is likely to report more benefit for reasons unrelated to receptor pharmacology.

  • Sex: Almost the entire controlled microdosing literature in which durable outcomes were measured is male. The two largest LSD microdosing trials enrolled only men, and the depression trial was 79% male. Marecki et al., 2026 document substantial sex-dependent differences in psychedelic pharmacodynamics, neuroplasticity and behavioural response in rodents, with ovarian cycle phase modulating several responses. Benefit estimates for women therefore rest on extrapolation.

  • Pre-existing health conditions: Depression and attention-deficit/hyperactivity disorder (ADHD — a condition of persistent inattention, impulsivity and restlessness) have been tested and diverge sharply: symptom reduction was seen in the uncontrolled depression trial, whereas a properly controlled ADHD trial found no advantage over placebo (Mueller et al., 2025), a trial sponsored by the pharmaceutical developer of the LSD formulation used (MindMed, now Definium Therapeutics), which likewise holds a direct commercial interest in the compound. Conditions treated with serotonergic medication modify response through pharmacological interaction rather than through the condition itself.

  • Age: Tolerability at 5, 10 and 20 micrograms has been established up to age 75 in a dedicated older-adult trial, with no impairment of cognition, balance or proprioception (the sense of where the body and limbs are positioned) (Family et al., 2020). Whether benefit differs at the older end of the target range is untested; the only age-stratified data address safety, not efficacy.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Anxiety and Dysphoria

Anxiety, together with the dysphoria (a persistent low, unpleasant mood state) that can follow repeated unpleasant dosing days, is the most common and most consequential adverse effect of microdosing LSD, and the leading reason participants discontinue. In the 80-participant home-administered trial, four participants in the LSD group withdrew because of treatment-related anxiety (Murphy et al., 2023); the same four withdrawals are reported in the pharmacokinetic analysis of that trial, where two had intermediate-to-weak CYP2D6 activity (Morse et al., 2025). Dose-finding work found significant increases in anxiety at both 5 and 20 micrograms and in confusion at 20 micrograms (Hutten et al., 2020), and the dedicated systematic review of microdosing side effects identified anxiety as one of the three most common adverse effects across 31 studies (Modzelewski et al., 2025). The effect is dose-dependent and resolves with the dose, but it recurs on subsequent doses in susceptible individuals.

Magnitude: Withdrawal for treatment-related anxiety in 4 of 40 participants (10%) in the largest repeated-dosing trial; significant anxiety elevation versus placebo at 5 and 20 micrograms.

Transient Cardiovascular Stimulation

Microdoses reliably raise blood pressure and, less consistently, heart rate for several hours. Elevated blood pressure was one of the three most common adverse effects identified across the microdosing literature (Modzelewski et al., 2025), and a placebo-controlled pain study found that 15 micrograms increased blood pressure on administration days, with blood pressure positively correlated to the outcome measure (Cavarra et al., 2025). The mechanism is combined serotonergic and adrenergic vasoconstriction and central sympathetic activation. In healthy participants the rise stays within the normal range and the maximal heart-rate increase after 10 micrograms was under 15% of baseline (Morse et al., 2025). The concern is not the magnitude in healthy people but the repetition of a pressor stimulus — a recurring blood-pressure-raising load — in anyone with uncontrolled hypertension or established coronary disease, a population systematically excluded from every trial to date (Nahlawi et al., 2025).

Magnitude: Mean blood pressure elevation within the normal range at 20 micrograms; maximal heart-rate increase under 15% above baseline at 10 micrograms.

Impairment of Cognitive Control

The most robust controlled finding in the entire field is a decrement, not an enhancement. A preregistered meta-analysis of 14 studies, 1,614 participants and 59 effect sizes found a significant decrease in cognitive control — the top-down capacity to inhibit responses, hold attention and switch tasks deliberately — with no detectable effect in any other cognitive domain (Pinhas et al., 2026). Neither substance, dose range, dosing duration nor assessment timing moderated the effect, and an umbrella review confirmed it as the sole consistent pooled signal in the literature (Özaydın & Canlan Özaydın, 2026). The effect is small and mechanistically coherent with a reduction in cognitive rigidity, which some would regard as the point of the practice; for anyone microdosing to sharpen focus or executive performance, it is the opposite of the intended result.

Magnitude: Pooled effect on cognitive control d = −0.34 (Cohen’s d — a standardised measure of effect size, where 0.2 is small and 0.5 moderate; 95% confidence interval −0.62 to −0.06) across 1,614 participants.

Medium 🟥 🟥

Perceptible Psychoactive Effects and Functional Impairment at the Upper Dose Range

The sub-perceptual premise fails at the top of the commonly used range. The threshold dose for psychotropic effect is 10 micrograms of LSD base; at that dose, ratings of being under the influence and of good drug effect rise significantly above placebo, beginning at 1.1 hours, peaking at 2.5 hours and ending at 5.1 hours, and at 20 micrograms bad drug effects also appear (Holze et al., 2021). Time perception is distorted across the 5–20 microgram range, with participants over-reproducing intervals of two seconds and longer, most markedly at 10 micrograms (Yanakieva et al., 2019). Because doses are usually taken on working days, the practical consequence is a multi-hour window of altered state during driving, machine operation or high-stakes decision-making. Clinical protocols address this by prohibiting driving on dosing days.

Magnitude: Perceptible drug effects from 10 micrograms, lasting approximately 4 hours (onset 1.1 h, offset 5.1 h); no perceptible effects at 5 micrograms.

Product Misidentification and Adulteration

Because there is no legal consumer supply, the compound obtained is not verifiably the compound intended. The principal hazard is substitution with N-benzylphenethylamine derivatives, marketed as NBOMe compounds, which are active on blotter at similar visual presentation but have a far narrower margin between an active and a toxic dose and have caused deaths from seizure, hyperthermia (a dangerous rise in body temperature) and cardiovascular collapse (Halberstadt, 2017). LSD itself has an extremely wide margin between an active and a lethal dose; its substitutes do not. A second failure mode is dose misestimation, since blotter content varies widely and the microdose target is one tenth to one twentieth of a full dose.

Magnitude: Fatalities documented with NBOMe compounds at doses in the low milligram range, against no confirmed human fatality from LSD overdose alone.

LSD is a Schedule I controlled substance in the United States, a Class A drug in the United Kingdom, and listed under Schedule I of the 1971 United Nations Convention on Psychotropic Substances. Possession carries criminal liability in most jurisdictions regardless of quantity or intent, and the sub-perceptual amount confers no legal distinction. The secondary consequences — professional licensing, security clearance, employment drug screening, custody proceedings, travel — are frequently more damaging than the primary penalty. This risk is deterministic rather than probabilistic and is entirely a function of jurisdiction.

Magnitude: Schedule I classification in the United States (no accepted medical use, highest control tier); Class A in the United Kingdom, carrying up to 7 years’ imprisonment for possession.

Low 🟥

Somatic Side Effects

Headache, nausea, gastrointestinal discomfort, appetite change, mild tremor and temperature dysregulation are reported across the microdosing literature. The systematic review of side effects characterised the profile overall as dose-dependent, mild and short-lived, resolving within the dosing day (Modzelewski et al., 2025), and naturalistic survey work found physiological discomfort to be among the most frequently cited drawbacks (Anderson et al., 2019). No trial has reported a serious or severe adverse event, abnormal laboratory value or clinically significant electrocardiogram change attributable to microdosing.

Magnitude: Mild, self-limiting and confined to the dosing day across 31 reviewed studies; no serious adverse events reported in any controlled microdosing trial.

Precipitation of Psychosis or Mania in Predisposed Individuals

Classic psychedelics at full doses can precipitate prolonged psychotic or manic episodes in people with a personal or family history of psychotic or bipolar disorder, which is why every clinical protocol excludes them; the evidence for this comes from case reports and non-clinical exposure rather than from trials, because the meta-analysis of adverse events across classic psychedelic trials found no persistent psychotic disorders at all in contemporary studies (Hinkle et al., 2024) — precisely because those trials screened the at-risk population out. No case of microdose-precipitated psychosis has been documented in a controlled trial, and trials systematically exclude the at-risk population, so the absence of cases carries little information. The grade reflects strong evidence at full doses and no direct evidence at microdoses.

Magnitude: Not quantified in available studies.

Speculative 🟨

Valvular Heart Disease from Chronic 5-HT2B Agonism

This is the single most consequential unresolved safety question, and the one that distinguishes microdosing from occasional full-dose use. LSD is a partial agonist at the 5-HT2B receptor with potency equal to or greater than at 5-HT2A (Tagen et al., 2023), and sustained 5-HT2B agonism is the established mechanism by which methysergide, pergolide and fenfluramine caused fibrotic valve disease and were withdrawn (Rouaud et al., 2024). Microdosing uniquely reproduces the chronic, repeated-exposure pattern those drugs shared, though the safety margin from typical microdose peak plasma concentrations is larger and exposure is short-lived — a few hours every second or third day rather than continuous. Direct evidence is limited and so far reassuring: chronic low-dose LSD produced no ventricular or valvular remodelling in mice on echocardiography at four and eight weeks, where serotonin and d-fenfluramine positive controls did (Effinger et al., 2025), and the first human study to perform echocardiography after repeated psychedelic administration found no clinical alteration after eight weeks (Daldegan-Bueno et al., 2026). Eight weeks is not the relevant timescale for a fibrotic process that took years to manifest with the withdrawn drugs, so the question stays open.

Hallucinogen Persisting Perception Disorder

Hallucinogen persisting perception disorder (HPPD — the persistence of visual disturbances such as trails, halos or static long after the drug has cleared) is a recognised, if uncommon, sequel to full-dose psychedelic use (Martinotti et al., 2018). Whether repeated sub-perceptual exposure can produce or contribute to it is unknown; no case attributed to microdosing has been reported in a controlled study, and systematic review of the condition finds the literature dominated by heavy full-dose exposure (Vis et al., 2021). The basis for including it is mechanistic plausibility and isolated case-report literature rather than evidence at microdose levels.

Risk-Modifying Factors

  • CYP2D6 and related enzyme genotypes: Intermediate or poor CYP2D6 metaboliser status raises plasma exposure from a fixed dose and is the one genetic signal so far linked to an adverse outcome: two of the four participants withdrawn for anxiety in the largest trial had intermediate-to-weak CYP2D6 activity (Morse et al., 2025). CYP1A2, CYP2B6 and CYP2C9 genotypes also appeared to influence concentration. The sample is far too small for a firm conclusion, and the authors call for study in larger cohorts.

  • Baseline blood pressure and cardiac status: Because every dose delivers a transient pressor stimulus, baseline blood pressure determines whether that stimulus stays within a benign range. Existing valvular disease is the other pivotal baseline: any degree of pre-existing regurgitation (backward leakage of blood through a valve that no longer closes fully) both raises the stakes of the 5-HT2B question and makes later attribution of change impossible without a baseline echocardiogram.

  • Sex: Beyond the near-total male composition of the trial literature, rodent work shows sex-dependent differences in pharmacokinetics, amygdala reactivity, dendritic spine formation and stress reactivity, with several responses stronger or qualitatively distinct in females and modulated by ovarian cycle phase (Marecki et al., 2026). Female risk estimates are therefore extrapolated, not measured.

  • Personal or family history of psychotic or bipolar disorder: This is the most important exclusionary characteristic in every clinical protocol, extending to first-degree relatives with a psychotic disorder and to significant prodromal symptoms (early warning signs that precede a full episode). It modifies not the probability of common side effects but the severity ceiling of the rare ones.

  • Pre-existing anxiety disorder: Since anxiety is the dominant adverse effect and the leading cause of discontinuation, an elevated anxiety baseline is the most likely modifier of tolerability. This is not directly quantified: trials recruited either healthy volunteers or people with depression or ADHD, not people with primary anxiety disorders.

  • Age: Repeated dosing at 5–20 micrograms was tolerated in adults with a mean age of 62.9 years, with no impairment of cognition, balance or proprioception and adverse-event frequency no higher than placebo (Family et al., 2020). Age nonetheless raises the prevalence of the conditions that matter — hypertension, coronary disease, degenerative valve change, use of multiple concurrent medications — so the modifier operates through comorbidity rather than through age itself. No trial has enrolled anyone over 75.

Key Interactions & Contraindications

  • Serotonergic antidepressants — selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors (SSRIs and SNRIs — the most widely prescribed antidepressant classes, e.g. fluoxetine, sertraline, escitalopram, venlafaxine, duloxetine): Severity — caution and expect attenuated response. Chronic use downregulates 5-HT2A receptors and blunts the subjective and physiological effects of classic psychedelics, an attenuation documented to persist for months after discontinuation (Gukasyan et al., 2023). Clinical consequence: loss of effect, and a temptation to escalate the dose into the perceptible range. Mitigating action: dose escalation is not the documented remedy; the LSD microdosing depression trial deliberately continued antidepressants in most participants rather than withdrawing them.

  • Monoamine oxidase inhibitors (MAOIs — an older antidepressant class that blocks the enzyme breaking down serotonin, dopamine and noradrenaline, e.g. phenelzine, tranylcypromine, moclobemide, and the antiparkinsonian selegiline): Severity — absolute contraindication in practice. Clinical consequence: unpredictable potentiation of serotonergic effect and, at higher exposures, serotonin toxicity. LSD’s direct receptor agonism means it is a weaker driver of serotonin toxicity than serotonin-releasing agents (Malcolm & Thomas, 2022), but the combination has no safety data at any dose. Mitigating action: complete avoidance; MAOI washout in clinical protocols is at least 14 days.

  • Lithium: Severity — absolute contraindication. Clinical consequence: multiple case reports describe seizures and prolonged, severe psychedelic reactions when lithium is combined with classic psychedelics, an interaction not seen with other mood stabilisers to the same degree. Mitigating action: none available; the combination is excluded from all clinical protocols.

  • Tricyclic antidepressants (e.g. amitriptyline, clomipramine, imipramine): Severity — caution. Clinical consequence: potentiation rather than attenuation of psychedelic effect is reported, so a nominal microdose can become perceptible. Mitigating action: where the combination is unavoidable, a halved starting dose and at least two weeks between titration steps.

  • Antipsychotics and 5-HT2A antagonists (e.g. risperidone, olanzapine, quetiapine, and the migraine agent cyproheptadine): Severity — blocking interaction. Clinical consequence: near-complete abolition of effect through competitive antagonism at the target receptor. Mitigating action: none needed for safety; this class is in fact the pharmacological rescue for an unwanted reaction.

  • Over-the-counter medications: Severity — caution. Dextromethorphan-containing cough preparations have serotonergic activity and monoamine oxidase inhibitor properties in some formulations; St John’s wort, sold without prescription in most markets, both induces CYP3A4 and adds serotonergic tone. Non-drowsy antihistamines (loratadine, cetirizine, fexofenadine) and standard analgesics (paracetamol, ibuprofen, aspirin) have no known interaction. Clinical consequence: additive serotonergic effect or altered LSD exposure. Mitigating action: complete separation of dextromethorphan use from dosing days.

  • Supplements with serotonergic or monoamine oxidase activity: Severity — caution to avoid. 5-hydroxytryptophan and L-tryptophan raise serotonin synthesis; S-adenosylmethionine, Rhodiola rosea, Griffonia simplicifolia extract and Syrian rue (Peganum harmala, a source of reversible monoamine oxidase inhibitors) all add serotonergic or enzyme-inhibiting activity. Clinical consequence: additive serotonergic effect of unpredictable magnitude. Mitigating action: discontinuation at least 48 hours before a dosing day, or substitution with a non-serotonergic alternative.

  • Supplements with additive cardiovascular or anxiety-provoking effects: Severity — caution. Because each dose transiently raises blood pressure and heart rate and can provoke anxiety, stimulant-adjacent supplements compound both. Caffeine, synephrine, yohimbine, higher-dose Panax ginseng and pre-workout formulations are the practical cases. Mitigating action: reduction or omission of stimulants on dosing days, with at least 4 hours between stimulant intake and the dose.

  • CYP-modifying agents: Severity — monitor. Strong CYP3A4 and CYP2D6 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit juice, paroxetine, fluoxetine, bupropion, quinidine) raise LSD exposure from a fixed dose, and strong inducers (rifampicin, carbamazepine, St John’s wort) lower it. Clinical consequence: a nominal microdose becoming perceptible, or becoming inert. Mitigating action: where a strong inhibitor cannot be avoided, dose reduction and re-titration from the lowest step.

  • Other interventions: Severity — caution. Ketamine, cannabis and MDMA (3,4-methylenedioxymethamphetamine — the stimulant sold recreationally as ecstasy) all have documented additive effects on anxiety and cardiovascular parameters with classic psychedelics; cannabis in particular reliably amplifies psychedelic intensity and anxiety. Alcohol is not pharmacologically dangerous in combination but compounds the impairment of cognitive control. Mitigating action: dosing days kept free of other psychoactive substances.

  • Populations who should avoid this intervention:

    • Anyone with a personal history of a psychotic disorder, bipolar disorder, or depressive disorder with psychotic features, or a first-degree relative with a psychotic disorder, or a Prodromal Questionnaire-16 score of 6 or above — the standard exclusion applied in current LSD trials.
    • Anyone with borderline personality disorder or current post-traumatic stress disorder, likewise excluded from current protocols.
    • Anyone with current or recent significant suicidal ideation or suicidal behaviour within the past 6 months.
    • Anyone with known or suspected valvular heart disease of any grade, or with pulmonary hypertension (raised blood pressure in the arteries supplying the lungs), given the unresolved 5-HT2B question.
    • Anyone with uncontrolled hypertension (resting blood pressure at or above 140/90 mmHg on repeated measurement), a myocardial infarction within 90 days, unstable angina, or a clinically significant arrhythmia.
    • Anyone taking lithium or a monoamine oxidase inhibitor.
    • Anyone who is pregnant, breastfeeding, or planning pregnancy.
    • Anyone with a current substance use disorder within the past 12 months, other than tobacco use.
    • Anyone with significant liver impairment (Child-Pugh Class B or C, the standard grading of how badly liver function is compromised), given that clearance depends entirely on the liver.
    • Anyone in a jurisdiction, occupation or legal situation where a controlled-substance finding carries consequences they are not prepared to accept.

Risk Mitigation Strategies

  • Low starting dose with stepwise upward titration: The two controlled dose-finding studies disagree at the bottom of the range: 5 micrograms elicited no significant acute subjective effect in one (Holze et al., 2021), and plasma levels were undetectable at that dose in the older-adult trial, whereas the other found significant increases in friendliness, arousal and anxiety at the same dose (Hutten et al., 2020); 10 micrograms is nonetheless the established threshold for perceptible psychotropic effect on both readings. A sequence of 5, then 8, then 10 micrograms, advancing only after at least two doses at each step, identifies the individual threshold without overshooting it. This mitigates the anxiety, dysphoria and functional impairment that are all dose-dependent, and protects slow metabolisers who reach unexpectedly high exposure from a nominal dose.

  • Identity and content verification before first use: Because the primary acute hazard is a substituted compound rather than LSD itself, reagent testing (Ehrlich reagent, which detects indoles — the chemical family LSD belongs to — and Hofmann reagent) and anonymous laboratory analysis through a testing service distinguish LSD from NBOMe derivatives and other substitutes. This mitigates the seizure, hyperthermia and cardiovascular collapse risk associated with N-benzylphenethylamine substitution.

  • Volumetric dosing rather than blotter division: Dissolving a known quantity in a measured volume of distilled water or high-proof alcohol and dispensing by syringe gives a reproducible dose; cutting blotter into fractions does not, because the compound is not evenly distributed across the paper. This mitigates the dose-misestimation route into perceptible effects and their attendant impairment.

  • Baseline echocardiogram with repeat imaging at 12 months: The 5-HT2B concern is the only plausible irreversible harm, and it is undetectable without imaging. A baseline study establishes existing valve status and makes any later change attributable; annual repetition is the interval used in cardiology surveillance of patients on drugs known to damage heart valves. This mitigates the risk of cumulative, silent valve change going undetected until it is symptomatic.

  • Paired blood pressure readings across the first several doses: The peak pressor effect coincides with peak plasma concentration at roughly 1.1 to 1.5 hours. Recording paired measurements across the first three to five doses establishes the individual response magnitude and identifies anyone whose rise is not benign. This mitigates the risk of repeatedly applying a pressor stimulus to an unrecognised hypertensive or vascular substrate.

  • Abstention from driving and machinery for at least 6 hours after a dose: Perceptible effects at 10 micrograms run from 1.1 to 5.1 hours, time perception is distorted across the microdose range, and cognitive control is measurably reduced. A 6-hour abstention covers the full window with margin. This mitigates the accident risk created by the impairment of cognitive control and altered time perception documented in controlled studies.

  • Dose scheduling on non-critical days, away from high-stakes cognitive work: Since the only reliable pooled cognitive finding is a decrement in top-down control, dosing before examinations, negotiations, surgery, flying or complex technical work inverts the intended effect. This mitigates the performance risk arising from reduced cognitive control.

  • Discontinuation at the first sign of recurrent anxiety: Anxiety was the sole cause of withdrawal in the largest trial and did not habituate. Stopping after two consecutive dosing days with unwanted anxiety, rather than persisting or escalating, mitigates the accumulation of a conditioned anxiety response and the dysphoria that follows repeated unpleasant dosing days.

  • Accessible 5-HT2A antagonist and the self-limiting nature of effects: Because the elimination half-life is approximately 3 hours and effects end by around 5 hours, an unwanted reaction at microdose levels resolves without intervention; where it does not, antipsychotics acting at 5-HT2A reverse the pharmacology directly. Awareness of this in advance mitigates the escalation of situational anxiety into panic.

Therapeutic Protocol

  • Standard schedules: Two regimens dominate. The one-day-on, two-days-off pattern derives from the protocol used in the first structured exploration of the practice by Fadiman & Korb, 2019 and is the most widely followed in naturalistic use. The clinical alternative is a fixed every-third-day or twice-weekly schedule: 10 micrograms every third day for six weeks in the Auckland healthy-volunteer trials, 20 micrograms twice weekly for six weeks in the Basel and Maastricht ADHD trial, and 6–20 micrograms twice weekly for eight weeks in the Auckland depression trials.

  • Dose range: Controlled trials have used 5 to 26 micrograms. The threshold for perceptible effect is 10 micrograms of LSD base; 5 micrograms is reliably sub-perceptual, 20 micrograms produces both good and bad drug effects in a substantial minority. Trials designed around genuine sub-perceptual exposure cluster at 8–13 micrograms.

  • Competing therapeutic approaches: The alternative to repeated sub-perceptual dosing is a small number of full doses given with psychological support, the model used in psilocybin- and LSD-assisted therapy for depression and anxiety. These are not variants of one intervention but pharmacologically and procedurally distinct approaches with different evidence bases, different risk profiles and different resource demands, and neither is established as the default. The cost gap between the alternatives is large and asymmetric: generic antidepressants cost a few cents per day, repeated sub-perceptual dosing is cheap in compound terms but reimbursed nowhere, and full-dose supervised therapy occupies two trained monitors for a full day per session. Institutional payers — private insurers and national health systems — therefore carry a systematic financial incentive to favour the cheapest established option and to resist adoption of the supervised model, which is a plausible source of structural bias both in how treatment guidelines are written and in which trials attract funding. A third approach under active development is the non-hallucinogenic structural analogue, engineered to retain plasticity effects without perceptual ones, which would remove both the impairment and the scheduling problem if it succeeds. The Auckland group (Muthukumaraswamy and colleagues) has done most to formalise the repeated-microdose model in trial form; the Basel group (Liechti and colleagues) and the Maastricht group (Ramaekers, Kuypers and colleagues) established the dose-response foundations; Eleusis Benefit Corporation pursued the older-adult and neuroinflammation framing commercially.

  • Time of day: Morning dosing is used in all clinical protocols and is the near-universal naturalistic practice. The rationale is twofold: the acute window of 1 to 5 hours falls within the working day rather than the evening, and given the observed extension of sleep on the following night, evening dosing risks interacting with sleep onset. No trial has compared morning against evening administration directly.

  • Half-life and dose splitting: The elimination half-life is approximately 2.7 to 3.1 hours, giving complete clearance well within a single day and no accumulation on any of the standard schedules. Every controlled trial has used a single daily dose; splitting a microdose is not practised and has no rationale, since the goal is a defined sub-threshold peak rather than sustained exposure.

  • Genetic influences on dose choice: CYP2D6, CYP1A2, CYP2B6 and CYP2C9 genotypes each appeared to influence plasma concentration from a fixed dose (Morse et al., 2025). Where pharmacogenetic data are already available, intermediate or poor CYP2D6 metaboliser status is a reason to start at the bottom of the range, since the two participants in that trial with weak CYP2D6 activity were among those withdrawn for anxiety. No protocol yet dose-adjusts on genotype prospectively.

  • Sex differences in dosing: No trial has dose-adjusted by sex, and no comparative data exist. Since the two largest LSD microdosing trials enrolled only men and rodent work shows sex-dependent pharmacodynamics modulated by ovarian cycle phase, women lack an evidence-based starting dose; the currently active premenstrual disorder trial deliberately times dosing to the luteal phase, which is the first protocol to treat cycle phase as a dosing variable.

  • Age-related adjustment: Repeated dosing at 5, 10 and 20 micrograms every fourth day over 21 days was tolerated in volunteers with a mean age of 62.9 years without cognitive, balance or proprioceptive impairment. No age-specific dose reduction is supported by data, but the longer four-day interval used in that trial is a reasonable default at the older end of the range, and the use of multiple concurrent medications makes interaction review more consequential than dose choice.

  • Baseline biomarkers influencing response: Baseline depression severity is the strongest predictor of measurable benefit, since healthy-volunteer trials show floor effects on mood instruments. Baseline blood pressure determines the acceptability of the acute pressor response. Chronic serotonergic antidepressant use predicts attenuated response.

  • Pre-existing conditions influencing response: Depression is the condition with the largest reported response and the weakest study design; ADHD has been tested rigorously and showed no advantage over placebo. Anxiety disorders predict poorer tolerability. Any condition requiring lithium, a monoamine oxidase inhibitor or an antipsychotic precludes the protocol on interaction grounds.

Discontinuation & Cycling

  • Intended duration: Every controlled trial has run for a fixed, bounded period — 21 days in the older-adult trial, six weeks in the healthy-volunteer and ADHD trials, eight weeks in the depression trials. No trial has run longer than eight weeks, so there is no evidence base for indefinite continuation, and the unresolved 5-HT2B question is a specific argument against treating the practice as lifelong. Naturalistic use frequently runs for months and is entirely uncharacterised beyond two months.

  • Withdrawal effects: None have been reported. LSD is not a dependence-forming compound: it does not produce compulsive use, and no withdrawal syndrome has been described in any microdosing trial on cessation, including in the trial where dosing ran for eight weeks with dose titration.

  • Tapering: No taper is required. Because there is no dependence, no receptor rebound and no accumulation between doses, cessation is abrupt in every trial protocol without adverse consequence. The only consideration is that any acute benefit ceases immediately, since the demonstrated effects are same-day.

  • Cycling and tolerance: Full-dose LSD produces rapid, marked tolerance across consecutive daily doses, which is the historical basis for the every-second-or-third-day pattern. At microdose levels this appears not to apply: Daldegan-Bueno et al., 2026 found no evidence of either tolerance or sensitisation across 16 doses over eight weeks, despite incremental dose titration. The conventional wisdom of built-in rest days is therefore historically motivated rather than empirically necessary at these doses, though it remains standard.

  • Planned breaks for reassessment: Because the acute effects are perceptible and expectancy-prone, a deliberate break of two to four weeks is the only practical way to distinguish a genuine effect from an accumulated belief. Every trial that measured baseline against endpoint found no durable change, which means a break should cost nothing measurable if the trial literature is right.

Sourcing and Quality

  • No legal consumer supply exists: LSD is a Schedule I controlled substance with no approved product, no pharmacy channel and no compounding pharmacy access in any major jurisdiction. Pharmaceutical-grade material of known purity exists only within licensed research supply chains and reaches individuals only through enrolment in a clinical trial or, in Switzerland and a small number of other jurisdictions, through limited compassionate-use authorisation. This is the defining sourcing fact and it has no workaround.

  • Grey-market analogues are a distinct product, not a substitute: Compounds such as 1cP-LSD, 1V-LSD, 1D-LSD and 1B-LSD are marketed as research chemicals in jurisdictions where they are not explicitly scheduled, and function as prodrugs converting to LSD. Their conversion efficiency, impurity profiles and dose equivalence are not characterised in peer-reviewed literature, and their legal status changes frequently. Treating them as interchangeable with LSD at a microgram-precise dose is not supportable.

  • Identity verification precedes content verification: Reagent testing kits (Ehrlich reagent, which turns purple with indoles including LSD; Hofmann reagent) rule in the indole class and rule out the N-benzylphenethylamine substitutes responsible for the serious acute harms in this space. Reagent testing establishes class, not quantity, and is a necessary but not sufficient step.

  • Third-party laboratory analysis is the only quantitative option: Anonymous mail-in analysis services operated by harm-reduction organisations, most prominently the Erowid-affiliated DrugsData programme, provide gas chromatography-mass spectrometry identification and, for some sample types, quantification. This is the closest available equivalent to a certificate of analysis and is the only way to know actual content per unit.

  • Formulation and stability determine reproducibility: LSD degrades on exposure to light, heat, oxygen and moisture, so blotter stored at ambient conditions loses potency unpredictably. Volumetric dilution into distilled water or high-proof alcohol, stored refrigerated in amber glass, gives a stable and dividable stock; clinical trials use standardised oral or sublingual solutions of known concentration for exactly this reason. Blotter division is the single largest source of dose error in naturalistic practice.

Practical Considerations

  • Time to effect: Acute effects are same-day and rapid, with peak plasma concentration at roughly 1.1 to 1.5 hours and perceptible effects at 10 micrograms beginning at 1.1 hours and ending at 5.1 hours. There is no evidence of a cumulative benefit that emerges over weeks: every controlled trial that compared baseline against six- or eight-week endpoint found no durable change in mood or cognition. Anyone expecting a build-up effect over a month is expecting something no trial has demonstrated.

  • Common pitfalls: Dose creep is the most frequent — escalating past the sub-perceptual threshold in search of a clearer signal, which converts a sub-perceptual practice into low-dose intoxication with the associated impairment. Unblinding oneself and then attributing the resulting expectancy to pharmacology is the second, and is why self-blinding protocols exist. Others include dosing before cognitively demanding work despite the documented decrement in cognitive control; dividing blotter rather than dosing volumetrically; assuming grey-market analogues are dose-equivalent to LSD; and continuing indefinitely without cardiac imaging.

  • Regulatory status: LSD is Schedule I in the United States, Class A in the United Kingdom, and controlled under Schedule I of the 1971 United Nations Convention on Psychotropic Substances in the 180-plus signatory states. There is no off-label pathway, because there is no approved label. Limited legal access exists through clinical trial enrolment, and Switzerland operates a restricted compassionate-use scheme for psychedelic-assisted therapy that is not a microdosing pathway. Decriminalisation measures in some United States jurisdictions reduce enforcement but do not confer legality.

  • Cost and accessibility: The compound itself is inexpensive at microdose quantities relative to almost any pharmaceutical intervention, since a single unit dose divides into ten or twenty microdoses. The real costs are not monetary: legal exposure, unverifiable supply, and the baseline and follow-up cardiac imaging that responsible use implies, which is neither reimbursed nor easily requested without disclosing the reason.

Interaction with Foundational Habits

  • Sleep: Direct and, on the available evidence, favourable in one narrow respect. Total sleep time increased by 24.3 minutes on the night following each dose in an objectively measured randomised controlled trial, with no reduction on the dosing day itself and no change in sleep stage proportions (Allen et al., 2024). The proposed mechanism is a modification of physiological sleep requirement through serotonergic effects on sleep-wake regulation. Practical consideration: clinical protocols place dosing in the morning, since the acute window runs to about 5 hours and evening dosing would put peak effect near sleep onset; the extra sleep on the following night is only observable where it is not truncated by a fixed alarm.

  • Nutrition: Indirect and mostly a matter of avoidance rather than support. No nutrient depletion is associated with LSD, and no dietary pattern is known to potentiate or blunt its effects. The relevant interactions run through the liver and through serotonin: grapefruit juice inhibits CYP3A4 and can raise exposure from a fixed dose, and tryptophan- or 5-hydroxytryptophan-containing supplements add serotonergic tone. Practical consideration: absorption timing is most reproducible on an empty or light stomach, and the two documented dietary interferences are grapefruit on dosing days and serotonergic supplements taken within 48 hours of a dose.

  • Exercise: Indirect, with one clear caution. There is no evidence that microdosing blunts or enhances training adaptation, and no trial has measured performance outcomes. The interaction is cardiovascular: each dose transiently raises blood pressure, and high-intensity or heavy resistance work superimposes a further large pressor load. Practical consideration: the 1-to-5-hour acute window is the period in which a hard session superimposes a second pressor load, so lower-intensity aerobic work is the better-matched option on dosing days, and reduced cognitive control is a poor match for technically demanding or heavily loaded lifting.

  • Stress management: Direct but bidirectional, and the least predictable of the four. Altered amygdala-cortical connectivity at 13 micrograms — increased with the angular gyrus, middle frontal gyrus and cerebellum, decreased with the postcentral and superior temporal gyri, with the frontal increase correlating with positive mood (Bershad et al., 2020) — and reported increases in psychological flexibility point toward a stress-buffering effect, while anxiety is simultaneously the most common adverse effect and the leading cause of discontinuation. The same pharmacology can go either way in the same person on different days. Practical consideration: because the demonstrated same-day effects include increased connectedness and reduced cognitive rigidity, pairing dosing days with meditation, breathwork or time outdoors is the most coherent use of the acute window; pairing them with high-conflict or high-pressure situations is the least, since these are the contexts in which the anxiety response is most likely to be triggered.

Monitoring Protocol & Defining Success

Baseline testing establishes both eligibility and the reference point against which any later change is judged. Because the one plausible irreversible harm is silent and cardiac, the baseline panel is weighted toward cardiovascular structure and function rather than toward the metabolic markers typical of other longevity interventions, and it is completed before the first dose rather than alongside it.

Ongoing monitoring follows a front-loaded cadence: blood pressure paired before and 2 hours after each of the first 3 to 5 doses, a review of tolerability and adverse effects at 2 weeks and 6 weeks, then blood pressure and a symptom review every 3 months for as long as dosing continues, with repeat echocardiography and electrocardiography at 12 months and annually thereafter.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Resting blood pressure 105–120 / 65–78 mmHg Every dose is a transient pressor stimulus; baseline determines whether that is benign Conventional threshold for hypertension is 130/80 mmHg, well above the functional target. Readings are taken seated after 5 minutes’ rest, with a pre-dose reading paired to a 2-hour post-dose reading on early doses
Resting heart rate 50–70 bpm Establishes the reference for the acute chronotropic (heart-rate-raising) response, which is under 15% above baseline at 10 micrograms Conventional reference range is 60–100 bpm, materially looser than the functional target. Best taken on waking before rising. Wearable-derived overnight values are acceptable if the same device is used throughout
Transthoracic echocardiogram (valve regurgitation grade) No regurgitation greater than trace at any valve; no leaflet thickening The only way to detect the 5-HT2B-mediated fibrotic valve change that is the central unresolved long-term risk Regurgitation is backward leakage of blood through a valve that no longer closes fully. This is the single most important baseline test and the one most often omitted. Repetition follows at 12 months and annually thereafter. Trace mitral or tricuspid regurgitation is common and benign; any aortic regurgitation or new leaflet thickening is treated as a stopping signal
12-lead electrocardiogram, corrected QT interval Under 430 ms (men), under 450 ms (women) Screens for the conduction abnormalities and arrhythmia substrate that would make repeated sympathetic stimulation unwise The QT interval is the time the heart’s electrical system takes to reset between beats, corrected here for heart rate. Conventional upper limits are 450 ms and 470 ms respectively; the tighter functional target leaves margin for any interacting medication that also prolongs the interval
High-sensitivity C-reactive protein (hs-CRP) Under 0.5 mg/L Provides an objective anchor for the anti-inflammatory hypothesis and flags any inflammatory process before starting hs-CRP is a blood marker of low-grade inflammation. Conventional low-risk cut-off is under 1.0 mg/L and the high-risk threshold 3.0 mg/L, both far looser than the functional target. Testing is deferred for 2 weeks after any infection, injury or heavy training block
Alanine aminotransferase (ALT) Under 20 U/L (men), under 17 U/L (women) Clearance depends entirely on the liver, so liver function determines exposure from a fixed dose ALT is a liver enzyme released when liver cells are stressed. Conventional upper limits near 40 U/L are far above the functional range. The sample is drawn fasting alongside the rest of a comprehensive metabolic panel
CYP2D6 genotype and predicted metaboliser phenotype Normal (extensive) metaboliser Intermediate and poor metaboliser status raises exposure from a fixed dose and is the one genotype so far linked to an adverse outcome A one-time test, not a repeated one. Often already available from prior pharmacogenomic panels. Intermediate or poor status is a reason to start at 5 micrograms rather than a reason to abstain
Montgomery-Åsberg Depression Rating Scale, self-report version Score under 7 (no depression) or a fall of at least 50% from baseline if starting elevated Provides the validated, quantitative mood endpoint against which any claimed durable benefit is judged Scoring is done at baseline and at 6 and 12 weeks, not on dosing days, since same-day scores capture the acute effect rather than the durable one. This is the instrument used in the LSD microdosing depression trials

Qualitative markers are tracked daily on both dosing and non-dosing days, since the entire question of whether the practice produces durable rather than same-day benefit turns on that comparison:

  • Sleep duration and quality: Objective total sleep time from a consistent wearable, given that this is the one endpoint with a demonstrated device-measured effect.
  • Perceived energy and motivation: Rated on dosing and non-dosing days separately, to expose whether any benefit is confined to the acute window.
  • Mood stability and irritability: Tracked daily rather than recalled weekly, since retrospective recall preferentially encodes dosing days.
  • Cognitive clarity and focused attention: Rated with explicit awareness that the pooled controlled evidence points to a decrement rather than a gain, so a reported improvement here is the strongest single candidate for an expectancy effect.
  • Anxiety: Any recurrent anxiety on dosing days is the primary stopping signal and is logged before it is rationalised.
  • Blinded self-check: A period of capsules prepared so that active and inactive doses are indistinguishable is the only way an individual can separate pharmacology from expectation, and it is the method that produced the largest placebo-controlled dataset in this field.

Emerging Research

  • Randomised successor to the open-label depression trial (LSDDEP2): The uncontrolled trial that reported a 59.5% depression score reduction has a registered randomised, double-dummy, triple-blind, active placebo-controlled parallel-groups successor, with the protocol published in advance (Daldegan-Bueno et al., 2024). It is a Phase 2b trial of an eight-week regimen of two titratable doses per week, with change in Montgomery-Åsberg Depression Rating Scale score as the primary endpoint. It has no clinicaltrials.gov identifier, being registered with the Australian New Zealand Clinical Trials Registry. Its use of an active placebo directly addresses the unblinding problem that undermines interpretation of every prior microdosing trial, and it is the single result most likely to settle whether the depression signal is pharmacological.

  • Targeted luteal-phase dosing in premenstrual disorders: NCT07189299 is a quadruple-masked, randomised, placebo-controlled three-arm study of 150 women, comparing 10 micrograms of LSD daily against 10 micrograms every other day against placebo, dosed during the late luteal phase across three menstrual cycles, with premenstrual symptom burden as the primary endpoint. It is the first microdosing trial designed around cycle phase and the first with a substantially female sample, which addresses the most conspicuous gap in the existing evidence base.

  • Completed trial that constrains the field: NCT05200936 tested 20 micrograms twice weekly for six weeks against placebo in 53 adults with ADHD and found the active arm no better than placebo, with both arms improving by a similar margin (Mueller et al., 2025). This is the most rigorous negative result in the field and materially weakens the case that microdosing produces durable attentional or executive benefit.

  • Microdosing trials in adjacent compounds: NCT07063862 is a recruiting Phase 3 trial of psilocybin microdosing for psychological and existential distress in palliative care, enrolling 120 participants, and NCT07449351 is a 20-participant early-phase study at Yale University pairing psilocybin microdosing with functional imaging and a full cognitive battery. Neither uses LSD, but both are powered and instrumented in ways the LSD literature is not, and a clear result in either direction will constrain interpretation of the LSD data.

  • Long-term cardiac safety: This is the area most likely to change the risk calculation. The theoretical case was set out by Tagen et al., 2023, whose Delos Therapeutics affiliation carries the commercial interest noted at first citation, and independently by Rouaud et al., 2024. The first direct tests have since arrived and point the other way: no ventricular or valvular remodelling in mice after chronic low-dose LSD where positive controls produced clear changes (Effinger et al., 2025), and no clinical alteration on the first human echocardiographic follow-up after repeated administration (Daldegan-Bueno et al., 2026). Longer-duration human imaging is the decisive missing piece.

  • Expectancy control methodology: Szigeti & Heifets, 2024 argue that expectancy effects in psychedelic trials are large enough to determine outcomes and that conventional blinding fails at any perceptible dose. If active-placebo and expectancy-controlled designs become standard, they could either dissolve the remaining positive findings or, conversely, vindicate them; Polito & Liknaitzky, 2024 set out eight specific reasons why the current placebo verdict may be premature, including small samples, narrow dose ranges and exclusive study of non-clinical populations.

  • Pharmacogenetic stratification: Morse et al., 2025 provide the first population pharmacokinetic model and validated assay for microdosed LSD and identify CYP2D6, CYP1A2, CYP2B6 and CYP2C9 as candidate determinants of exposure and response. Genotype-stratified trials would test whether the heterogeneous results across studies reflect metaboliser mix rather than genuine null effects, an explanation that would strengthen the case for the intervention if confirmed and weaken it if excluded.

  • Sex as a biological variable: Marecki et al., 2026 document sex-dependent differences in psychedelic pharmacokinetics, dendritic spine formation, amygdala reactivity and stress response in rodents, with ovarian cycle phase modulating several. Given that the human microdosing evidence is overwhelmingly male, incorporating sex-stratified analysis could either extend the current findings to women or reveal that they do not transfer.

Conclusion

Microdosing LSD means taking an amount far below what produces an altered state, usually every second or third day, in the hope of steadier mood, sharper thinking, and better brain health. It is absorbed within about an hour and cleared within a few hours, acting mainly on the serotonin system that shapes mood and the brain’s capacity to change.

The controlled evidence is thinner than the enthusiasm around it. Studies in which neither participants nor researchers knew who received the real substance do find same-day effects: modest lifts in mood, energy and felt creativity, and longer sleep the night after a dose. They do not find the lasting improvements in mood or thinking that most people take up the practice for. Where comparison against a dummy tablet has been strictest, the popular claim of sharper thinking not only fails but tips slightly the other way, toward a small loss of focused mental control. Side effects are usually mild and brief; anxiety is the most common reason people stop.

What remains unknown is what years of regular use do. No human study has run that long, and a concern about heart-valve tissue, raised by this compound’s kinship to withdrawn medicines, has only recently been examined directly. Much of the evidence on both sides is funded by firms with a stake in the answer — MindBio, Eleusis, MindMed and Delos among them — so confident claims in either direction rest on an evidence base with its own interests.

Top - Benefits - Risks - Protocol